Drug safety alert extended to men

Posted 12 March 2025 PM 

Results of a retrospective observational study has prompted Sanofi to update the label of its anticonvulsant Epilim in Australia to warn about paternal exposure and the potential risk of neurodevelopmental disorders as a precaution with generic drugmakers following suit.

It is well known that sodium valproate can cause malformations and neurodevelopment disorders in babies born to women taking valproate before and during pregnancy. Because of this, women and people who can give birth to children are advised to avoid taking this medicine at those times.

To see the whole article, please login